Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Wrist Replacement Devices Market Forecast to Grow

By HospiMedica International staff writers
Posted on 11 Apr 2013
Wrist surgery is embracing more and more technologically advanced endeavors, in an effort to provide arthritis patients with improved freedom of movement. More...
These are the latest findings of GlobalData (London, United Kingdom), an international business intelligence provider.

According to the report, the global patient population is set to swell, due to an increasingly aging population that will suffer persistent wrist pain caused by degenerative osteoarthritis (OA), traumatic arthritis, rheumatoid arthritis (RA), and gout. The two main surgical solutions to these problems are total wrist replacement (TWR) and total wrist fusion (TWF). TWF provides significant pain relief (but at the expense of wrist motion), while in contrast, TWR focuses on preserving wrist motion, allowing patients the ability to continue with daily activities.

TWF has historically been the more popular option, with much less risk of complications than TWR, which requires extensive bone resection. But TWR has been gaining momentum as a choice for patients who want to retain more motion and have more functional use of their hand; long-term clinical efficacy still needs to be proven, since the majority of TWR clinical trials so far have been only short-term studies, and failure rates and complication rates have been high beyond five years of implantation, making it a challenge for physicians to justify TWR procedures.

Several types of implants are available, constructed from silicone, titanium, and polyethylene, and recent improvements in TWR implant design has shown marked improvement, with issues of implants loosening and small bone perforation being resolved. Orthopedic surgeons have also called for TWR devices with alternative materials and coatings to give better biological fixation. Increasing popularity among patients and doctors will drive technology to improve further, as competition increases amongst current TWR players and new companies looking to enter the market.

Both surgical solutions still need some perfecting before they are embraced by the masses, and an additional consideration is that better surgical training is needed, as joint replacement for the wrist is a complex surgical procedure with a high learning curve for the surgeon. Physicians have stated that refined instrumentation is required to obtain more successful implantation.

The TWR sales market across the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, China, and India was worth an estimated USD 32.1 million in 2012, and this value is predicted to grow at a compound annual growth rate (CAGR) of 6.08%, reaching USD 46.1 million by 2018. The TWF market was estimated to be worth USD 30.4 million in 2012 across the same markets, and is estimated to reach over USD 33.7 million by 2018, representing a CAGR of 1.67%.

Related Links:

GlobalData




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.